GHK-Cu in Australia: What the Evidence Shows
Published 16 August 2026
GHK-Cu in Australia: What the Evidence Shows
GHK-Cu has one of the longer research histories of any compound in this space — but the way it's increasingly discussed today doesn't always match the form that history is actually built on.
What Is GHK-Cu?
GHK-Cu is a naturally occurring tripeptide — three amino acids (glycine, histidine and lysine) bound to a copper ion — first isolated from human plasma in 1973 (Pickart & Thaler, 1973, foundational identification). It occurs naturally in human plasma, saliva and urine, with circulating levels that decline with age (Pickart & Thaler, 1973).
What the Research Shows
GHK-Cu has decades of established use in topical cosmetic formulations aimed at skin and wound care, supported by a substantial published literature going back to the 1970s (Pickart & Thaler, 1973). More recent research has also examined the compound in animal models for other applications, including a 2023 study looking at skeletal muscle pathways (Deng et al., 2023).
What's Still Unclear
There are currently no published human studies examining GHK-Cu given by injection. This is a meaningful gap: the way a compound behaves when applied topically to skin is not the same as how it behaves when introduced systemically, and the two evidence bases shouldn't be treated as interchangeable.
Copper in particular is known to accumulate in the liver over time. This is a pharmacokinetic question that has been well studied for dietary and topical copper exposure, but has not been studied for injected use of this specific compound — leaving a genuine unknown about how injected GHK-Cu would be processed and cleared by the body over repeated use.
Regulatory Status in Australia
GHK-Cu is not listed on the Australian Register of Therapeutic Goods (ARTG) and does not carry Therapeutic Goods Administration (TGA) approval for any therapeutic use. Read more about how peptide consultation pathways are coordinated across Australia.
Where This Leaves You
Established topical use and untested injectable use are two very different evidence pictures, even though they share a compound name. If GHK-Cu has come up in your own research — particularly in the context of injectable use — that distinction is worth raising directly with an independent, registered healthcare practitioner, who can walk you through what the topical evidence does and doesn't tell us about other routes of use.
Related Reading
- How to Access Legal Peptide Support in Australia
- BPC-157: What the Research Actually Shows
- CJC-1295 in Australia: What the Evidence Shows
- Back to Peptides Hub
GL Vitality Drips operates as a concierge coordination service only. We do not provide, supply, or grant access to any therapeutic good.
References
A note on this article
This article is general educational information only. It is not medical advice, and it is not a representation that any substance is safe, effective or approved for any purpose. It is not intended to promote the use, purchase or supply of any therapeutic good. Substances that have not been evaluated by the TGA carry unknown risks, including possible side effects, interactions with other medicines and unknown long-term safety.
GL Vitality Drips is a consultation coordination and administrative support service. We do not diagnose, treat, or prescribe, and GL Vitality Drips does not provide, supply, or grant access to any therapeutic good. Any consultation, assessment or pharmacy dispensing is arranged solely by independent, registered healthcare practitioners and licensed Australian pharmacies, subject to their own eligibility criteria. Not all individuals will be suitable candidates, and no outcome is guaranteed.
